A5047026897- Hematopoietic Stem Cell Transplantation
- Cancer Genomics and Diagnostics
- Renal cell carcinoma treatment
- Mesenchymal stem cell research
- Pancreatic and Hepatic Oncology Research
Universidade Federal Fluminense
2025
IPO Porto
2022
Objective Disease-free survival (DFS) is frequently used as the primary endpoint in trials of adjuvant and neoadjuvant therapies for early-stage pancreatic cancer (PC), but its validity a surrogate overall (OS) remains uncertain. This study evaluates strength consistency DFS OS PC trials. Methods analysis systematic review meta-analysis followed Preferred Reporting Items Systematic Reviews Meta-Analyses guidelines. Trials involving drug therapy were identified through PubMed, Embase Cochrane...
PURPOSE Early-onset pancreatic cancer (EOPC) is an emerging global health concern, defined as (PC) diagnosed before age 50 years. This study aims to evaluate trends in EOPC incidence, mortality, and associated risk factors, with projections of future burden through 2040. METHODS A population-based analysis was conducted using the Global Burden Diseases, Injuries, Risk Factors Study 2021 data set, encompassing from 204 countries territories. PC individuals 15-49 Statistical analyses...
Background: Allogeneic hematopoietic stem cell transplantation (alloHSCT) is a therapeutic option with curative intent in hematological malignancies. Despite improvements alloHSCT, relapse of the underlying disease still one main causes mortality. Donor lymphocyte infusion (DLI) an immunotherapy that can be used after alloHSCT patients high-risk (prophylaxis), mixed donor chimerism or minimal residual (preemptive) and (therapeutic). derived graft versus tumor effects induce durable remission...
Background: Graft-versus-host disease (GVHD) continues to be the major lethal complication of allogeneic hematopoietic stem cell transplantation (HCT). The standard first-line therapy for acute GVHD is high-dose steroids, but 50% cases are steroid refractory (SR), typically involving gastrointestinal (GI) tract. Unfortunately, there no established second-line which response rates low (20–40%) and overall survival poor, highlighting urgent need better therapies. Aims: Evaluate prognostic...